Asset Details
Do you wish to reserve the book?
Behçet’s Syndrome
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Behçet’s Syndrome
Do you wish to request the book?
Behçet’s Syndrome
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Behçet’s Syndrome
2024
Overview
To the Editor:
In their review, Saadoun et al. (Feb. 15 issue)
1
discuss recent developments related to Behçet’s syndrome. Inflammation-driven endothelial-cell dysfunction is the main cause of thromboembolism in patients with Behçet’s syndrome.
2
Glucocorticoids and immunosuppressants are standard care in these cases. However, the authors’ statement that the role of anticoagulants is uncertain might be misleading, and the decision about using them remains dependent on the clinical context and pathophysiological features. For example, it was found that antiphospholipid antibodies may be present in patients with Behçet’s syndrome during thrombotic events, with an estimated prevalence as high as 50% in some . . .
Publisher
Massachusetts Medical Society
Subject
/ Antibodies, Antiphospholipid - analysis
/ Antibodies, Antiphospholipid - immunology
/ Anticoagulants - therapeutic use
/ Behcet Syndrome - complications
/ Behcet Syndrome - drug therapy
/ Behcet Syndrome - immunology
/ Humans
/ Immunosuppressive Agents - therapeutic use
/ Male
/ Regions
/ Thrombosis - prevention & control
/ Ulcers
